Q4 2025 · 13F-HR
GENERAL ATLANTIC, L.P.holdings as filed
Filed 2026-02-17 · accession 0000950142-26-000395
$2.87B
Reported value
13
Positions
2025-12-31
Period end
The Brief · GENERAL ATLANTIC, L.P. · Q4 2025
AI · grounded in 13F
GENERAL ATLANTIC, L.P. closed its position in AKRO, reducing exposure by $272.2M. The fund established a new position in NRIX valued at $92.9M. Other activity included increasing holdings in RVMD by 13.7% and CHYM by 10.7%, while trimming its stake in ALHC by 45.8%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G29018101 | DLO | DLOCAL | $659.7M | 23.0% | 46,656,695 | Common | SOLE |
| 16935C109 | CHYM | CHIME | $535.1M | 18.6% | 21,259,683 | Common | SOLE |
| G98239109 | XP | XP, INC | $371.6M | 12.9% | 22,699,133 | Common | SOLE |
| 01644J108 | ALKT | ALKAMI | $276.6M | 9.63% | 11,991,480 | Common | SOLE |
| 01625V104 | ALHC | ALIGNMENT HEALTHCARE | $260.1M | 9.05% | 13,167,733 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES | $224.0M | 7.80% | 2,812,928 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS | $222.9M | 7.76% | 8,031,252 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS | $153.0M | 5.33% | 6,117,715 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS | $92.9M | 3.23% | 4,897,159 | Common | SOLE |
| 29882P106 | EWCZ | EUROPEAN WAX CENTER | $47.2M | 1.64% | 13,110,492 | Common | SOLE |
| M8216R109 | RSKD | RISKIFIED | $26.5M | 0.92% | 5,324,998 | Common | SOLE |
| 39957D201 | GROV | GROVE COLLABORATIVE | $2.7M | 0.09% | 2,474,859 | Common | SOLE |
| G9572D103 | BULL | WEBULL | $394,840 | 0.01% | 50,816 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.